Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Leading Edge Health Inc.
WARNING LETTER
•Leading Edge Health Inc.•May 1, 2026

Leading Edge Health Inc. – FDA Warning Letter, May 1, 2026

Record Details

On June 17, 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to Leading Edge Health Inc. following an evaluation of the company"s website conducted in May 2026. The agency identified significant violations of the Federal Food, Drug, and Cosmetic Act regarding the marketing of two specific products: "Erectin Stimulating Gel" and "VigRX Delay Wipes." The FDA determined that these items are classified as unapproved new drugs because they are intended to treat medical conditions or affect the structure and function of the body without prior agency approval. For instance, the company marketed the products for physical performance and therapeutic effects such as numbing and improved circulation. Because these products are not generally recognized as safe and effective for their advertised uses, their distribution in interstate commerce is illegal. The FDA has instructed Leading Edge Health Inc. to investigate the root causes of these violations and implement corrective measures. The company is required to submit a written response within 15 business days outlining the steps taken to address the issues and prevent future occurrences. Failure to comply with these requirements may result in further legal actions, including product seizures or injunctions.

Company
Leading Edge Health Inc.
Inspection date
May 1, 2026
Product type
drugs
Office
Office of Unapproved Drugs & Labeling Compliance
Person
  • Tina Smith (Director)
View Company Profile

ID · 3aa0f482-8635-4c4a-b740-48ad1ee1d5e7

Violation Codes10
21 CFR 201.12821 U.S.C. 321(p)21 U.S.C. 355FD&C Act 201(p)(1)FD&C Act 201(g)(1)FD&C Act 301(d) of the FD&C Act21 U.S.C. 331(e)FD&C Act 505FD&C Act 505(a)21 U.S.C. 355(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Leading Edge Health Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.